Literature DB >> 24316096

Mixed high and low grade bladder tumors--are they clinically high or low grade?

Ofer N Gofrit1, Galina Pizov2, Amos Shapiro2, Mordechai Duvdevani2, Vladimir Yutkin2, Ezekiel H Landau2, Kevin C Zorn2, Guy Hidas2, Dov Pode2.   

Abstract

PURPOSE: The pathological grade of bladder cancer has an immense impact on patient treatment and prognosis. While most bladder tumors show pure high or low grade patterns, some show a mixed pattern. We explored the incidence and clinical significance of this phenomenon.
MATERIALS AND METHODS: A total of 642 patients with a mean age of 67.5 years underwent transurethral resection of nonmuscle invasive bladder tumors between June 1998 and December 2008, including 156 and 454 with low and high grade lesions, respectively. In 32 patients (5%) mixed grade tumors were found, defined as low grade tumors with 10% or less of a high grade component. All patients were followed a median of 60 months postoperatively.
RESULTS: Mean age, the proportion of men and the proportion of stages Ta/T1 in patients with mixed grade tumors were between those of the high and low grade groups. Five-year recurrence-free survival was similar for high, low and mixed grade tumor types (56.9%, 63.8% and 66.4%, respectively, p=0.252). Five-year progression-free survival was significantly lower in patients with high grade disease (73.9%, p<0.0001) but similar in those with high and mixed grade tumors (99% and 96.9%, respectively, p=0.167). Similarly, disease specific survival was significantly worse in patients with high grade tumors (p<0.0001) but similar in those with high and mixed grade lesions (p=0.679).
CONCLUSIONS: Mixed grade is found in about 5% of nonmuscle invasive tumors, representing a patient group with unique clinical features. The clinical course of patients with mixed grade tumors parallels that of patients with low grade tumors.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  carcinoma; mortality; neoplasm grading; urinary bladder; urothelium

Mesh:

Year:  2013        PMID: 24316096     DOI: 10.1016/j.juro.2013.11.056

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  SIU-ICUD on bladder cancer: pathology.

Authors:  Eva Compérat; Marek Babjuk; Ferran Algaba; Mahul Amin; Fadi Brimo; David Grignon; Donna Hansel; Ondra Hes; Bernard Malavaud; Victor Reuter; Theo van der Kwast
Journal:  World J Urol       Date:  2018-09-14       Impact factor: 4.226

2.  Mixed low- and high-grade non-muscle-invasive bladder cancer: a histological subtype with favorable outcome.

Authors:  Tina Schubert; Matthew R Danzig; Srinath Kotamarti; Rashed A Ghandour; Danny Lascano; Byron P Dubow; G Joel Decastro; Mitchell C Benson; James M McKiernan
Journal:  World J Urol       Date:  2014-08-23       Impact factor: 4.226

Review 3.  A practical guide to bladder cancer pathology.

Authors:  Eva Compérat; Justine Varinot; Julien Moroch; Caroline Eymerit-Morin; Fadi Brimo
Journal:  Nat Rev Urol       Date:  2018-01-31       Impact factor: 14.432

4.  Dataset for the reporting of carcinoma of the bladder-cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Authors:  E Compérat; J R Srigley; F Brimo; B Delahunt; M Koch; A Lopez-Beltran; V Reuter; H Samaratunga; J H Shanks; T Tsuzuki; T van der Kwast; M Varma; F Webster; D Grignon
Journal:  Virchows Arch       Date:  2020-01-08       Impact factor: 4.064

5.  Noninvasive low-grade papillary urothelial carcinoma with degenerative nuclear atypia: a grading pitfall.

Authors:  Andres Matoso; Vamsi Parimi; Jonathan I Epstein
Journal:  Hum Pathol       Date:  2021-04-19       Impact factor: 3.526

6.  The Clinical Impact of Tumor Grade Heterogeneity in Non-muscle-invasive Urothelial Carcinoma of the Bladder.

Authors:  Meftun Culpan; Ferhat Keser; Ayberk Iplikci; Gozde Kir; Gokhan Atis; Asif Yildirim
Journal:  Medeni Med J       Date:  2021-12-19

Review 7.  Bladder Cancer Sample Handling and Reporting: Pathologist's Point of View.

Authors:  Roberta Mazzucchelli; Daniela Marzioni; Giovanni Tossetta; Laura Pepi; Rodolfo Montironi
Journal:  Front Surg       Date:  2021-12-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.